Proactive Investors - Run By Investors For Investors

Scancell surges after announcing milestone in development of its solid tumours treatment

Scancell has a clinical development partnership with Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research
Cancer article in a newspaper
Scancell's ImmunoBody immunotherapy platform activates the body's immune system

Scancell Holdings PLC (LON:SCLP) and the cancer charity Cancer Research UK have announced further progress with Scancell's SCIB2 cancer immunotherapy vaccine.

Pre-clinical studies have demonstrated that the administration of SCIB2 as a liposomal nanoparticle results in potent immune responses and prolonged survival.

READ Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The nanoparticle technology uses known lipid (soluble biomolecules) carriers that are optimised to deliver SCIB2 DNA to immune cells. The liposomal nanoparticles protect the DNA from degradation and facilitate efficient uptake, expression and T-cell activation against cancer cells, said Scancell.

The nanoparticle delivery system provides an alternative approach to electroporation - an electrical technique that involves the application of high-voltage electric pulses in short bursts – that has been used to deliver other ImmunoBody agents to patients.

Cancer Research UK is now planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.

Dr Cliff Holloway, the chief executive officer of Scancell, said the latest milestone “moves us one step closer to entering the clinic”.

“This new nanoparticle approach to deliver SCIB2 is expected to achieve results that are as effective as, or even better than, electroporation. We believe SCIB2 has the potential to provide a much-needed treatment option for patients suffering from a range of common solid tumours including NSCLC, the most frequent cause of cancer death globally,” Holloway added.

Dr Nigel Blackburn, Cancer Research UK's director of drug development, said the vaccine could bring about urgently needed improvements for some cancer treatments.

“Our collaboration with Scancell, combining extensive expertise and experience in drug development, will help bring this treatment to the patients that need it sooner,” Blackburn declared.

Shares in Scancell were up 12% at 4.75p in early deals.

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

salmon
January 30 2019
Long-term fundamentals remain firmly in the seafood specialist's favour.
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use